CN105267195A - Composition and application of composition to acute renal failure resisting drugs - Google Patents
Composition and application of composition to acute renal failure resisting drugs Download PDFInfo
- Publication number
- CN105267195A CN105267195A CN201510755587.1A CN201510755587A CN105267195A CN 105267195 A CN105267195 A CN 105267195A CN 201510755587 A CN201510755587 A CN 201510755587A CN 105267195 A CN105267195 A CN 105267195A
- Authority
- CN
- China
- Prior art keywords
- renal failure
- acute renal
- composition
- compositions
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition, a preparation method and application of the composition to preparation of acute renal failure resisting drugs. Through pharmacological experiments, the composition is capable of resisting acute renal failure and has acute renal failure resisting drug development value.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to compositions, preparation method and its usage.
Background technology
Acute renal failure (AcuteRenalFailure, ARF) be the clinical syndrome caused by many reasons, be found in clinical departments patient, sickness rate is high and often have serious consequences, its feature is that (a few hours are to a couple of days) renal function sharply declines in a short time, clinical manifestation is acute oliguria (urine volume <400mLPd) or anuria (urine volume <100mLPd), in body, nitrogen matter metabolite is discharged and is produced obstacle, there is azotemia rapidly, water and electrolyte, acid base imbalance, and cause each system corresponding function imbalance of whole body.The principal element of acute renal failure is caused to be the sharply minimizing of renal blood flow, and the oxidative stress caused due to nephridial tissue ischemia and cell injury, finally cause the deterioration of renal tissue structural damage and function.There is no the generally acknowledged effective medicine for the treatment of acute renal failure clinically at present, only by correcting water-electrolyte balance, correcting the symptomatic treatment measures such as acidosis and improving symptom, the later stage also needs to maintain body function by hemodialysis.Improving kidney perfusion obstacle and alleviating in Renal tissues damage and have the clinical medicine of obvious curative effects rare.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The Compound I that the present invention relates to is one and delivers (Fan-YuMengetal. in 2011, 2011.SchiglautoneA, aNewTricyclicTriterpenoidwithaUnique6/7/9-FusedSkeletonf romtheStemsofSchisandraglaucescens.OrganicLetters13 (2011) 1502 – 1505) compound, we have carried out structural modification to Compound I, obtain two new derivants and compound III and compound IV, and prepared compositions by compound III and compound IV and the anti-acute renal failure activity of said composition is evaluated, it is active that it has anti-acute renal failure.
Summary of the invention
The invention discloses a new compositions, said composition is made up of compound III and compound IV, and in said composition, the mass percent of compound III and compound IV is respectively 55% and 45%.
Compositions disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
The object of this invention is to provide the purposes that compositions is used for the treatment of acute renal failure, namely for the preparation of the purposes for the treatment of acute renal failure medicine.
Compositions of the present invention has obvious therapeutical effect to acute renal failure disease.
Find that compositions can improve the function of kidney by our research.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 compound S chiglautoneA
Document (the Fan-YuMengetal. that the people such as the preparation method reference Fan-YuMeng of compound S chiglautoneA (I) deliver, 2011.SchiglautoneA, aNewTricyclicTriterpenoidwithaUnique6/7/9-FusedSkeletonf romtheStemsofSchisandraglaucescens.OrganicLetters13 (2011) 1502 – 1505) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2SchiglautoneA
By Compound I (502mg, 1.00mmol) be dissolved in 15mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.08g), 1,50% sodium hydroxide solution of 2-Bromofume (7.520g, 40.00mmol) and 6mL.Mixture stirs 8h at 35 degrees Celsius.After 8h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 3 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.0, v/v), collects brown concentrated elution band and flings to the brown ceramic powder (508mg, 71%) that namely solvent obtains Compound II per.
1HNMR(500MHz,DMSO-d
6)δ13.40(s,1H),6.10(s,1H),5.63(s,1H),5.53(s,1H),3.85(d,J＝11.2Hz,4H),3.52(d,J＝10.8Hz,4H),2.96(s,1H),2.20(s,1H),2.16(s,2H),2.00(s,1H),1.84(d,J＝13.9Hz,4H),1.69(s,1H),1.58(dd,J＝22.2,8.5Hz,4H),1.51(s,1H),1.47(s,1H),1.26(dd,J＝9.1,4.4Hz,4H),1.21(s,1H),1.08–0.98(m,4H),0.96-0.94(m,9H),0.94-0.85(m,6H).
13CNMR(125MHz,DMSO-d6)δ211.46(s),209.14(s),170.06(s),161.12(s),143.51(s),132.01(s),127.77(s),85.96(s),82.40(s),70.19(s),69.10(s),57.14(s),52.73(s),51.90(s),45.77(s),40.67(s),38.57(s),38.32(s),35.04(s),33.55(s),33.27(s),29.85(s),28.98(s),26.71(s),25.50(s),24.05(s),22.31(s),21.06(s),20.56(s),20.00(s),18.69(s),18.11(s),15.07(s).
HRMS(ESI)m/z[M-H]
-calcdforC
34H
51Br
2O
6:715.2032；found715.2027.
The synthesis of O-(diethylin) ethyl derivative (III) of embodiment 3SchiglautoneA
Compound II per (358mg, 0.5mmol) is dissolved in the middle of 10mL acetonitrile, adds Anhydrous potassium carbonate (690mg wherein, 5.0mmol), potassium iodide (168mg, 1.0mmol) and diethylamine (2920mg, 40mmol), mixture reflux 8h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction 2 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.0, v/v), collects brown concentrated elution band and flings to the brown ceramic powder (231.2mg, 66%) that namely solvent obtains compound III.
1HNMR(500MHz,DMSO-d6)δ20.07(s,1H),6.13(s,1H),6.06(s,1H),5.55(s,1H),3.52(d,J＝5.1Hz,4H),3.01(s,1H),2.89(s,8H),2.72(s,2H),2.64(s,2H),2.40(s,2H),2.22(s,1H),2.10(s,1H),1.89(d,J＝18.6Hz,4H),1.72(d,J＝8.4Hz,2H),1.62(d,J＝11.5Hz,2H),1.55(s,1H),1.50(s,1H),1.40(d,J＝9.3Hz,2H),1.33–1.27(m,3H),1.25(s,1H),1.14(s,12H),1.08–0.60(m,19H).
13CNMR(125MHz,DMSO-d6)δ211.64(s),209.43(s),170.46(s),161.60(s),144.10(s),132.71(s),127.95(s),86.25(s),82.80(s),67.46(s),66.70(s),57.84(s),52.91(s),52.75(s),52.29(s),48.15(s),46.37(s),41.36(s),38.76(s),38.62(s),35.42(s),34.04(s),30.43(s),29.67(s),26.91(s),25.78(s),24.44(s),22.81(s),21.64(s),21.25(s),20.20(s),18.97(s),18.50(s),15.57(s),12.85(s).
HRMS(ESI):m/z[M+H]
+calcdforC
42H
73N
2O
6:701.5469；found:701.5465。
The synthesis of the O-(two hydroxyethylamines) ethyl derivative (IV) of embodiment 4SchiglautoneA
Compound II per (358mg, 0.5mmol) is dissolved in 15mL acetonitrile, adds Anhydrous potassium carbonate (0.345g, 2.5mmol), potassium iodide (0.084g, 0.5mmol) and diethanolamine (1.0514g, 10mmol), mixture reflux 9h.Pour in cold water by reactant liquor after reaction terminates, with dichloromethane extraction three times, merge organic facies, use water and saturated common salt water washing successively, anhydrous sodium sulfate drying, concentrating under reduced pressure removes solvent.Product, with purification by silica gel column chromatography (petroleum ether/acetone 100:1, v/v), obtains the faint yellow solid (0.199g, 52%) of compound IV.
1HNMR(500MHz,DMSO-d6)δ17.77(s,1H),6.00(s,1H),5.40(s,1H),5.20(s,1H),3.37(d,J＝17.8Hz,4H),3.28(s,8H),2.87(s,1H),2.51(d,J＝6.5Hz,4H),2.43(s,8H),2.24(s,2H),2.06(d,J＝12.7Hz,2H),1.76–1.68(m,5H),1.57(s,1H),1.53–1.39(m,8H),1.36(s,1H),1.24(s,1H),1.20–1.14(m,3H),1.11(s,1H),0.94–0.82(m,10H),0.80(s,3H),0.76(s,3H),0.72(d,J＝20.0Hz,3H).
13CNMR(125MHz,DMSO-d6)δ211.39(s),208.98(s),169.80(s),160.73(s),143.02(s),131.42(s),127.05(s),85.91(s),82.25(s),66.70(s),65.63(s),58.62(s),56.55(s),56.61(s),53.30(s),52.45(s),51.52(s),45.29(s),40.06(s),38.52(s),38.17(s),34.73(s),33.17(s),29.35(s),28.38(s),26.34(s),25.00(s),23.45(s),22.05(s),20.67(s),20.07(s),19.31(s),18.41(s),17.73(s),14.59(s).
HRMS(ESI):m/z[M+H]
+calcdforC
42H
73N
2O
10:765.5265；found:765.5261。
Embodiment 5 compositions is to the therapeutical effect of acute renal failure rat
(1) experimental technique
The preparation of compositions: loaded by the powder of 45mg compound IV crossing 200 order nets after crossing the powder of the 55mg compound III of 200 order nets and grinding after grinding to mix in tubule with cover and with turbine stirring instrument and namely obtain 100mg compositions, obtains the solution of compositions by the compositions of this 100mg of water dissolution during use.
Intramuscular injection glycerol is adopted to cause Acute Renal Failure Rats animal model.Select the healthy male SD rat 30 of 180 ~ 220g, be divided into 5 groups at random: sham operated rats (intramuscular injection normal saline); Model group (intramuscular injection glycerol); Administration intervention group (compositions, compound III or compound IV 0.6mg/Kg, intramuscular injection glycerol), each group rat tail vein injection saline or treat reagent thing immediately after glycerol modeling, is administered once after 12 and 24 hours again.
(2) observation index
Metabolic cage collection twenty-four-hour urine is put into after the administration of rat last or normal saline, stay latter 6 hours of urine with 4% chloral hydrate intraperitoneal injection of anesthesia, adopt laser Doppler flowmetry to measure after modeling and bilateral renal blood flow after treatment, average as single animal renal blood flow; Get blood and prepare serum, measure blood BUN and Cre (all by the operation of test kit description).
(3) experimental result
1. compositions can increase acute renal failure Mouse Kidney blood flow
Compositions significantly can increase acute renal failure Mouse Kidney blood flow, and compound III and compound IV act on without this.
Table 1 compositions is on the impact of acute renal failure Mouse Kidney blood flow
* P<0.05vs acute renal failure model group
2. compositions is to the protective effect of acute renal failure Mouse Kidney function tool
Acute renal failure rat intravenous injection normal saline is after 24 hours, and serum BUN and Cre is in table 2.Acute renal failure model group, apparently higher than sham operated rats, illustrates that model group animal renal function injury is serious.Compositions can improve the renal function (P<0.05) of acute renal failure rat, and compound III and compound IV act on without this.In table 2.
The each rats in test groups renal function index of table 2 compares
* P<0.05vs acute renal failure model group
Conclusion: compositions can protect the function of kidney, can be used for preparing anti-acute renal failure medicine.And compound III and compound IV can not protect kidney, should not be used to prepare anti-acute renal failure medicine.
The preparation of embodiment 6 composition tablet involved in the present invention
Get 2 grams of compositionss, add the customary adjuvant 18 grams preparing tablet, mixing, conventional tablet presses makes 100.
The preparation of embodiment 7 composition capsule involved in the present invention
Get 2 grams of compositionss, add prepare capsule customary adjuvant as starch 18 grams, mixing, encapsulatedly makes 100.
Claims (6)
1. a compositions, it is characterized by said composition and be made up of compound III and compound IV, in said composition, the mass percent of compound III and compound IV is respectively 55% and 45%,
2. the preparation method of compositions as claimed in claim 1, is characterized by: the powder of compound III and the powder of compound IV are respectively 55% and 45% according to mass percent and fully mix.
3. the application of compositions as claimed in claim 1 in treatment acute renal failure medicine.
4. the application of compositions as claimed in claim 3 in treatment acute renal failure medicine, is characterized by: the reduction of the renal blood flow amount caused by described composition for improved acute renal failure.
5. the application of compositions as claimed in claim 3 in treatment acute renal failure medicine, is characterized by: the rising of the serum BUN that described composition for improved acute renal failure causes.
6. the application of compositions as claimed in claim 3 in treatment acute renal failure medicine, is characterized by: the rising of the change of serum C re that described composition for improved acute renal failure causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755587.1A CN105267195A (en) | 2015-11-09 | 2015-11-09 | Composition and application of composition to acute renal failure resisting drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510755587.1A CN105267195A (en) | 2015-11-09 | 2015-11-09 | Composition and application of composition to acute renal failure resisting drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105267195A true CN105267195A (en) | 2016-01-27 |
Family
ID=55137600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510755587.1A Pending CN105267195A (en) | 2015-11-09 | 2015-11-09 | Composition and application of composition to acute renal failure resisting drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105267195A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074525A (en) * | 2016-06-13 | 2016-11-09 | 南京广康协生物医药技术有限公司 | The composition of Schiglautone A derivative is used for preparing anti-acute renal failure medicine |
-
2015
- 2015-11-09 CN CN201510755587.1A patent/CN105267195A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| FAN-YU MENG ET. AL.: "Schiglautone A, a New Tricyclic Triterpenoid with a Unique 6/7/9-Fused Skeleton from the Stems of Schisandra glaucescens", 《ORGANIC LETTERS》 * |
| 赵淑美: "五味子抗肾衰竭小议", 《山东中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074525A (en) * | 2016-06-13 | 2016-11-09 | 南京广康协生物医药技术有限公司 | The composition of Schiglautone A derivative is used for preparing anti-acute renal failure medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083383B (en) | The application in preparing anti-acute renal failure medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN105267195A (en) | Composition and application of composition to acute renal failure resisting drugs | |
| CN104095856B (en) | The application in preparing anti-acute renal failure medicine of the diethylamine derivative of Cleistanone Cleistanone | |
| CN105287585A (en) | Composition and application of composition in medicine for resisting acute renal failure | |
| CN105343082A (en) | Composition and application of composition in medicines for resisting acute renal failure | |
| CN105193793A (en) | Composition and application thereof in anti-ARF (Acute Renal Failure) drugs | |
| CN105213395A (en) | Compositions and the application in anti-acute renal failure medicine thereof | |
| CN105380950A (en) | Composition and application thereof to acute renal failure resistant drug | |
| CN104434929B (en) | The application in preparing anti-acute renal failure medicine of O-(piperazinyl) ethyl derivative of Cleistanone | |
| CN104784190A (en) | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparation of medicine for resisting acute renal failure | |
| CN105250289A (en) | Composition and application thereof to acute renal failure (ARF) resistant medicines | |
| CN105250307A (en) | Composition and application thereof to acute renal failure (ARF) resistant medicines | |
| CN105287463A (en) | Composition and application thereof to acute renal failure (ARF) resistant medicines | |
| CN105343076A (en) | Composition and application thereof in acute renal failure resisting drug | |
| CN105030773A (en) | Composition 64083001030526 and application thereof in acute renal failure resisting medicine | |
| CN105125556A (en) | Composition and application thereof in drugs for resisting acute renal failure | |
| CN104906091A (en) | Application of O-(diethylin)ethyl derivative of Daphmalenine A in preparing acute renal failure resisting drugs | |
| CN104784176A (en) | Application of derivative of Daphmalenine A in preparation of acute renal failure resisting drugs | |
| CN106822107A (en) | The imidazole radicals of Psiguadial A and two hydroxyethylamine derivative compositions are used for anti-acute renal failure | |
| CN105232512A (en) | Composition and application thereof to drugs for treating or preventing renal fibrosis | |
| CN106038542A (en) | Application of composition of Artalbicacid derivatives in preparation of acute renal failure resistant drugs | |
| CN106074534A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-acute renal failure medicine | |
| CN104666310A (en) | Application of O-(triazolyl) ethyl derivative of Cleistanone in preparation of medicine resistant to acute renal failure | |
| CN106176734A (en) | The application in anti-acute renal failure medicine of the compositions of O (triazolyl) ethyl of Schiglautone A and O (two (2 methylmercaptoethyl) amido) ethyl derivative | |
| CN105343044A (en) | Composition and application thereof in anti-rhinitis drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160127 |
|
| RJ01 | Rejection of invention patent application after publication |